BIOGRAPHY

Michael Schultze

Dr. Michael Schultze leads a dedicated team of Real-World Evidence (RWE) experts in designing and implementing secondary data-driven non-interventional studies.

Alongside his managerial responsibilities for the RWE secondary data department, Michael is responsible for the development of medical algorithms and the interpreting of big medical data sets of secondary data projects. These projects cover diverse topics such as Epidemiology, HEOR and Safety, and a broad range of therapy areas.

His interdisciplinary experience combines the three areas of expertise essential for secondary data-related studies: medical expertise, advanced project management skills, and a profound understanding of working with Real-World Data (RWD). With his in-depth knowledge of current opportunities, challenges, needs, and limitations of RWE and RWD, Michael is also ideally placed to consult regarding RWE in general and different study designs to bridge the growing need for leading-edge secondary data methodologies with classical post-authorization safety and efficacy studies.

Michael holds a doctorate and a state examination degree in Veterinary Medicine, both from the Ludwig Maximilian University of Munich, Germany.

PUBLICATIONS

2026
Patient Burden in the Treatment of Wilson Disease in the United States: An Analysis of Real-World Health Insurance Claims Data from the Komodo database Hedera Peter, Teynor Megan, Strader Carey, Costantino Halley, Michael Schultze, Akumo Divine, Weiss Karl Heinz 2026 Advances in Therapy → DOI
Other
2025
Epidemiology of generalized pustular psoriasis in Germany: Analyzing factors influencing prevalence estimates from claims data. Michael Schultze, Kossack Nils, Kromer Christian, Zimmermann Thomas M., Nikolaus Kolb 2025 JDDG: J Dtsch Dermatol Ges.. 2025; 10.1111/ddg.15633. → DOI
Dermatology
Real-world psoriasis treatment patterns and disease burden in Germany, with a focus on biologics and apremilast: data from a German statutory health insurance database Pinter Andreas, Schulte Marcus, Kossack Nils, Marc Pignot, Michael Schultze, Feldhus Andrea 2025 JME: Journal of Medical Economics. 2025; VOL. 28, NO. 1, 207-220. 10.1080/13696998.2025.2452054. → DOI
Dermatology
Real-world treatment patterns and survival outcomes in patients with locally advanced squamous cell carcinoma of the head and neck in Germany using claims data Hering Kathrin, Kuhnt Thomas, Kossack Nils, Richter Lena M., Michael Schultze, Osowski Ulrike, Henkel Luisa, Gaupel Ann-Christin, Solbes Marie-Noelle, Zolyniak Bernard, Schoenherr Nancy 2025 Front. Oncol. 2025; Vol. 15:1547311. 10.3389/fonc.2025.1547311. → DOI
Oncology
2024
Epidemiology of Wilson disease in Germany – real-world insights from a claims data study Fang Shona, Hedera Peter, Borchert Julia, Michael Schultze, Weiss Karl Heinz 2024 Orphanet J Rare Dis. 2024; 10.1186/s13023-024-03351-2. → DOI
Other
2022
Prevalence of lupus nephritis among patients with systemic lupus erythematosus in Germany N Hunnicutt Jake, Michael Schultze, Garal-Pantaler Elena, Marc Pignot, Georgiou Mary Elizabeth, Gairy Kerry 2022 Nephrology Dialysis Transplantation, Volume 37, Issue Supplement_3, May. 2022; 10.1093/ndt/gfac071.036. → DOI
Other
Clinical and economic burden of hypertrophic obstructive cardiomyopathy in Germany Sedaghat-Hamedani F., Zema C., Michael Schultze, Borchert J., Zhong Y., Bluhmki T., Krause T., Schmoelders J., Meder B. 2022 DGK Herztage 29.09 – 01.10.2022. 2022; 10.1007/s00392-022-02087-y. → DOI
Other
2020
Real-World Cost Difference in Patients With Psoriasis Initiating Apremilast vs. Secukinumab After Conventional Systemic Therapy Using German Sickness Fund Data Kossack Nils, Schoenfelder T., Michael Schultze, Marc Pignot, Mehta S., Nazareth T., Walzer S. 2020 DDK KOMPAKT 2020. JDDG Volume 18 Issue S1. 2020. 2020; 10.1111/ddg.14021. → DOI
Dermatology

Get in touch

Send a message to the team member.